Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) today announced that its lead oncology compound, zoptarelin doxorubicin (formerly AEZS‑108), met the primary endpoint of the investigator-driven and sponsored Phase 2 clinical trial in Castration- and Taxane-Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.

Crystal Research Associates has released a slide presentation on Catasys, Inc. (CATS-OTC) to summarize major facets of Catasys' treatment program, value proposition for health insurance providers, and market opportunities, as presented in greater detail in the 56-page Executive Informational Overview available for download here.

Crystal Research Associates has released a 56-page Executive Informational Overview (EIO) on healthcare service and data analytics company, California-based Catasys, Inc. The EIO details Catasys' business model, technology development, customers and end users, treatment approach, opportunities in the behavioral healthcare market, competition, and more. The report is available for download below.